Wellgistics Health, Inc. has launched the diabetes drug Brenzavvy to its network of 6,500 independent pharmacies.
The launch targets the $16 billion SGLT-2 inhibitor market, focusing on the 33 million type II diabetics in the US.
The aim is to reduce out-of-pocket costs for patients and provide a patient-education revenue opportunity for pharmacists.
Target Market
Addresses the 33 million Americans with type II diabetes facing high out-of-pocket costs for SGLT-2 drugs.
Technology Integration
Integrating EinsteinRx™ AI platform into the Wellgistics Pharmacy Network to educate patients and providers on Brenzavvy advantages.
Market Potential
Aims to capture a share of the $16.8 billion SGLT-2 inhibitor market with projected growth to $28.9 billion by 2033.
- Wellgistics' launch of Brenzavvy sets a new model for patient-specific drug advantages in the diabetes market.
- Pharmacists empowered by EinsteinRx™ will optimize therapy selection without increasing out-of-pocket costs for patients.
The launch of Brenzavvy signifies a strategic move by Wellgistics Health to address the unmet needs of type II diabetics and improve market access for innovative drug therapies.